Principal Investigators: Arora
Inthera Bioscience AG is a Swiss biotech company which develops novel small chemical molecules that act as inhibitors of cellular processes that are essential to tumor cells.
Inthera has selected to target biological characteristics which are of fundamental importance in cancer cells characterized by a high replication and proliferation rate.
Currently in late preclinical development, the lead molecule INTH-454 is a new chemical entity that specifically and effectively targets such tumor cells. INTH-454 inhibits DNA replication, interferes with the control of the cell cycle, and induces DNA damage in tumor cells.